Imbalance of Type I and II Interferon Pathways in Sjögren’s Disease and Pain Perception

02 Apr 20264 min read0 viewsJournal Feed

GIST

In this real-life study, researchers evaluated circulating interferons (IFNs) in Sjögren’s disease (SjD), systemic lupus erythematosus (SLE), and healthy controls, focusing on absolute levels and inter-IFN ratios. Plasma concentrations of IFN-α2, IFN-β, IFN-γ, IFN-λ1, and IFN-λ2 were measured, with disease activity and patient-reported outcomes assessed by ESSDAI, ESSPRI, and SLEDAI-2K.

Absolute IFN levels did not differ significantly among groups. In SjD, exploratory analyses found a significant association between the IFN-α2/IFN-γ ratio and pain severity (ESSPRI), independent of systemic inflammatory activity as measured by ESSDAI (Spearman ρ = 0.48; adjusted p < 0.05).

Ratios involving IFN-λ showed differences between SLE and SjD, suggesting disease-specific interferon balance patterns. No significant associations were observed between IFN parameters and SLEDAI-2K scores in SLE.

The authors propose that the relative balance of interferon pathways, rather than absolute IFN levels, may have clinical relevance for pain in SjD, and posit that IFN subtype ratios could serve as exploratory biomarkers of immune dysregulation. They call for further studies integrating systemic, tissue-level, and transcriptomic data to validate these findings.

Clinical Editorial

Summary

Interferon Pathway Balance in Sjögren’s Disease: A Focus on Pain Perception

Context and aims

The study investigates the systemic relevance of circulating type III interferons and the clinical implications of the balance among type I, II, and III interferons in Sjögren’s disease (SjD), contrasting findings with systemic lupus erythematosus (SLE) and healthy controls.

Study design and populations

This real-life exploratory analysis measured plasma levels of IFN-α2, IFN-β, IFN-γ, IFN-λ1, and IFN-λ2.
Participants included 59 SjD patients, 35 SLE patients, and 30 healthy controls.
Disease activity and patient-reported outcomes were captured using ESSDAI, ESSPRI, and SLEDAI-2K.
In addition to absolute cytokine levels, ratios among interferon subtypes were evaluated to reflect pathway balance.

Key methods and analytic approach

The primary emphasis was on the relative balance of interferon signals rather than individual cytokine concentrations.
Non-parametric statistics with adjustment for multiple testing were employed.

Main findings and signals

Absolute concentrations of individual IFN subtypes did not show significant differences across the three groups.
In SjD, a significant association emerged between the IFN-α2/IFN-γ ratio and pain severity as measured by ESSPRI (Spearman’s ρ ≈ 0.48; adjusted p < 0.05).
This association persisted independently of systemic inflammatory activity as gauged by ESSDAI.
Differential IFN-λ–related ratios distinguished SLE from SjD, suggesting disease-specific interferon-balance patterns.
In SLE, no significant relationships were observed between IFN parameters and SLEDAI-2K scores.

Interpretation and implications

The relative balance among interferon pathways may be more clinically informative than absolute IFN levels in SjD, particularly for patient-reported pain burden.
IFN subtype ratios hold potential as exploratory biomarkers of immune dysregulation in SjD and may reflect disease-specific signaling dynamics.
The study posits that systemic, tissue-level, and transcriptomic integration is necessary to validate and extend these observations.